Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
2cureX ABFRA:2QE +0.38%37 Pretax Margin % is -8,850.00% as of Jun. 2025. GuruFocus rates FRA:2QE with a GF Score™ of 37/100. The stock has 3 warning signs investors should review. Among 942 Biotechnology companies, 2cureX AB ranks worse than 95.12% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. 2cureX AB's Pre-Tax Income for the
six
months ended in Jun. 2025 was €-0.18 Mil. 2cureX AB's Revenue for the
six
months ended in Jun. 2025 was €0.00 Mil. Therefore, 2cureX AB's pretax margin for the quarter that ended in Jun. 2025 was -8,850.00%.
The historical rank and industry rank for 2cureX AB's Pretax Margin % or its related term are showing as below:
FRA:2QE'
s Pretax Margin % Range Over the Past 10 Years
Min: -33077.78 Med: -20788.89 Max: -8500
Current: -20800
FRA:2QE's Pretax Margin % is ranked worse than 95.12% of 942
companies
in the Biotechnology industry
Industry Median: -89.895
vs FRA:2QE: -20800.00
2cureX AB (FRA:2QE) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
2cureX AB Pretax Margin % Related Terms
2cureX AB Pretax Margin % Historical Data
* Premium members only.
The historical data trend for 2cureX AB's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2QE vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, 2cureX AB's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
2cureX AB Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 2cureX AB's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where 2cureX AB's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2cureX AB (FRA:2QE) has a Pretax Margin % of -8,850.00% as of Jun. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on 2cureX AB and its competitors. According to the industry distribution chart, 2cureX AB ranks #896 out of 942 companies in the Biotechnology industry, placing it in the top 95.1%.
Is 2cureX AB's Pretax Margin % too high?
2cureX AB's current Pretax Margin % is -8,850.00%. Based on the distribution chart, 2cureX AB ranks #896 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, 2cureX AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does 2cureX AB's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 2cureX AB ranks #896 out of 942 companies for Pretax Margin %. This places 2cureX AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on 2cureX AB and its competitors. 2cureX AB's current Pretax Margin % is -8,850.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 2cureX AB stock overvalued right now?
2cureX AB (FRA:2QE) has a current Pretax Margin % of -8,850.00%. The current Pretax Margin % is -8,850.00%. 2cureX AB's overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For 2cureX AB (FRA:2QE), the current Pretax Margin % is -8,850.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.
37GF Score
Get the complete analysis for FRA:2QE
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2QE has been successfully added to your 
